E-cigarettes and the lungs
Respiratory effects of vaping and e-cigarettes.
Papers per year
Each bar is 12 months; the last one ends 17 Oct 2026. New trials in the same years: 21, 17, 13, 14, 16.
New guidelines and consensus this year
All papers from the last 12 months
305 papers (18 Oct 2025 – 17 Oct 2026), newest first. Loading the full list…
- Caryocar coriaceum fixed oil attenuates E-cigarette Aerosol-Induced pulmonary injury and oxidative stress in miceJ Ethnopharmacol2027 Jan 10PMID 42480878
- Impact of Non-Tobacco Nicotine Products on Postoperative Outcomes in Soft Tissue Hand SurgeryJ Hand Surg Glob Online2027 JanPMID 42741232
- Sub-acute dihydroxyacetone exposure alters mitochondria and induces cardiac strainToxicol Rep2026 DecPMID 42835281
- The impact of vitamin E and its acetate derivative on lipid dynamics of unsaturated membrane systemsBiochim Biophys Acta Biomembr2026 Oct 16PMID 42887631
- Application of PTR-ToF-MS for detecting and tracking E-liquid aroma compounds in exhaled breathJ Breath Res2026 Oct 8PMID 42790470
- A diagnostic dilemma: autoimmune pulmonary alveolar Proteinosis unmasked by vaping-induced lung injuryOxf Med Case Reports2026 OctPMID 42836177
- Updates in COPD Management: From Inflammatory Pathways to Targeted TherapiesEur J Clin Invest2026 OctPMID 42773542Review
- Use of electronic cigarettes and asthma across the lifespanJ Allergy Clin Immunol2026 OctPMID 42526604Review
- Electronic cigarettes, smoking and lung cancer risk: some evidence about the continuum of harmNat Rev Clin Oncol2026 OctPMID 42521773
- EVALI and Beyond: An Update on the Spectrum of Vaping-Associated Lung PathologyAm J Surg Pathol2026 Oct 1PMID 42438307
More pulmonology trends
All specialties →Antifibrotics in pulmonary fibrosis
Nintedanib, pirfenidone and newer antifibrotics.
Biologics in severe asthma
Biologic therapies for severe asthma.
Key point: Biologic choice in adult severe asthma can be impacted by quality of life impairment, lung function, exacerbation frequency, oral corticosteroid use, endotype, biomarkers and comorbidities.
Lung cancer screening
Low-dose CT screening for lung cancer.
Key point: Low-dose CT screening reduces lung cancer death risk by at least 21% and should be offered to people aged 50–75 with at least 20 pack-years.
Sotatercept
An activin signalling inhibitor for pulmonary arterial hypertension.
Interstitial lung abnormalities
Incidental interstitial changes on CT and their significance.
Ensifentrine
An inhaled PDE3/PDE4 inhibitor for COPD.
Key point: Ensifentrine significantly improved lung function, symptoms and quality of life versus placebo in Chinese individuals with COPD, with similar adverse event rates.
Too many papers to read?
PubDaily picks the ones that matter in your specialty and summarises them, about 10 minutes a week.
How these numbers are counted
PubMed query, searched in titles and abstracts by publication date:
("e-cigarette*"[tiab] OR vaping[tiab] OR "electronic cigarette*"[tiab]) AND (lung[tiab] OR respiratory[tiab] OR pulmonary[tiab])Trials: ClinicalTrials.gov studies first submitted in each 12-month window that match the same terms. A query can miss synonyms or catch unrelated papers, so treat counts as approximate.